linjc16/ctgov huggingface dataset:
Skin Microbiome of Chinese Population Cohort Study

Study Overview
=================
Brief Summary
-----------------
This observational study aims to investigate the relationship between public health and the skin microbiome in the province of Zhejiang. Due to the lack of current research on the skin microbiome, the following general questions will be investigated in this study: 1) What connection exists between dietary practices and facial skin microbiome? 2) How do people's lifestyle routines affect the facial skin microbiome? 3) What effects does the altered living environment have on people's facial skin microbiomes? 4) How do the seasons affect people's facial skin microbiomes? Every 3 to 4 months, the participants' facial skin microbiota samples will be taken, and they will be asked to complete a survey.

Official Title
-----------------
Skin Microbiome of Chinese Population Cohort Study: Association Between Human Health and Skin Microbiome

Conditions
-----------------
Skin Microbiome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages from 15 to 50. Exclusion Criteria: a severe medical history, including a history of surgery or medication, or serious illnesses such as cancer, liver disease, kidney disease, or craniocerebral trauma. recent medical treatment (topical antibiotics, corticosteroids, and other anti-inflammatory drugs within 4 weeks, and systemic antibiotics, corticosteroids, and other immunosuppressive drugs within 6 months)

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in facial microbiota profiling | Quantitative and qualitative analysis of bacteria population from the sample, rRNA and metagenome sequencing will be conducted on each sample | Day 1, Day 90, Day 180, Day 270, and Day 360 |
Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
Positron Emission Tomography - Computed Tomography (PET-CT) using fluorine-18 fluorodeoxyglucose is a functional imaging diagnostic tool which is widely used In several neoplastic conditions, at initial staging, for restaging in suspected disease relapse and for assessing the response to treatment. Most patients with multiple myeloma (MM) exhibit a high-glycolytic activity rate and therefore they are FOG-avid, especially at the disease relapse. The priceless value of 18F-FOG PET-CT in the therapeutic assessment for several treatment schemes, including aSCT, has been highlighted by several studies: particularly, the occurrence of negative PET-CT after a double aSCT in MM patients with clinical complete response or very good partial response positively correlates with favourable PFS and overall survival (OS). likewise, persistence of 18F-FDG avid disease in MM patients achieving a clinical complete response constitutes a poor prognostic factor. Primary objective of this prospective, observational, non-pharmacological, multicentric study is to evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment with daratumumab in patients with .relapsed/refractory MM.

Official Title
-----------------
Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic accuracy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with refractory multiple myeloma who relapsed after therapy with daratumumab in combination with dexamethasone + bortezomib or dexamethasone + lenalidomide; patients capable of expressing informed consent. Exclusion Criteria: patients with clinical contraindications to the administration of daratumumab; patients with coexisting non-hematological neoplastic condition; patients< 18 years; patients uncapable of expressing informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 18F-FDG PET-CT to predicting response to treatment and to predicting prognosis in patients with relapsed/refractory multiple myeloma. | Positron Emission Tomography - Computed Tomography (PET-CT) using fluorine-18 fluorodeoxyglucose to assess early response after 6 months of treatment with daratumumab in 10 patients with relapsed/refractory multiple myeloma. | 1 year |
Postoperative Delirium After Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
This project is a retrospective evaluation of the routine data of patients who underwent a kidney transplant at the Charité Campus Mitte between January 2015 and December 2019 (until the corona pandemic).

Detailed Description
-----------------
Post-anesthetic complications such as delirium can occur in patients after kidney transplantation. We would therefore like to characterize pathophysiological changes after transplantation of the kidneys and, if necessary, gain diagnostic and therapeutic knowledge. The purpose is to study postoperative delirium after kidney transplantation.

Official Title
-----------------
Postoperative Delirium After Kidney Transplantation

Conditions
-----------------
Post-operative Delirium

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients 18 years and older who underwent kidney transplantation and who were admitted to Post-intensive care unit or to an Intensive care unit at the Campus Charité Mitte Exclusion Criteria: Incomplete data records of the parameters to be determined Underage Patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of delirium | Incidence of delirium is recorded from validated delirium scores. | 2015 - 2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of delirium | Duration of delirium is recorded in days. | 2015 - 2019 | 
| Severity of delirium | Severity of delirium is recorded from validated delirium scores. | 2015 - 2019 | 
| Intraoperative parameter | Intraoperative parameter are recorded from patients with delirium. | 2015 - 2019 | 
| Anesthesia | Anesthesia is recorded from patient files of patients with delirium. | 2015 - 2019 | 
| Anesthesiological parameters | Anesthesiological parameters are recorded from patient files of patients with delirium. | 2015 - 2019 | 
| Immunosupressive therapy | Immunosupressive therapy is recorded in patients with delirium. | 2015 - 2019 | 
| Delirium treatment | Delirium treatment is recorded peri-operatively. | 2015 - 2019 | 
| Pain teatment | Pain treatment is recorded peri-operatively. | 2015 - 2019 | 
| Intensive care unit stay | Length of intensive care unit stay is measured in days. | 2015 - 2019 | 
| Hospital stay | Length of hospital stay is measured in days. | 2015 - 2019 | 
| Mortality | Mortality is measured within the hospital | 2015 - 2019 |
Data Collection Protocol for Patients With Von Hippel Lindau Disease

Study Overview
=================
Brief Summary
-----------------
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.

Detailed Description
-----------------
Primary Objectives: Obtain prospective and retrospective data on lesion development, surgical history and systemic therapy use in patients with vHL disease Assess genotype-phenotype correlation between VHL mutation type and patterns of lesion development Assess genotype-phenotype correlation for response to belzutifan in an organ-specific manner Secondary Objectives: --Obtain quality of life data in patients with vHL disease

Official Title
-----------------
Data Collection Protocol for Patients With Von Hippel Lindau Disease

Conditions
-----------------
Von Hippel Lindau Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of genetic confirmation or clinical criteria consistent with vHL disease. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: • Patients with psychiatric illness/social situations that would limit compliance with study requirements.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival (PFS) |  | through study completion; an average of 1 year |
Biomarkers in Pulsed Field Ablation Versus Cryoballoon Ablation

Study Overview
=================
Brief Summary
-----------------
Our study will include consecutive patients undergoing pulsed field ablation (PFA) or cryoballoon (CBA) ablation. Tissue injury and inflammation markers will be measured before and after the procedure.

Detailed Description
-----------------
Study population: The participants with symptomatic atrial fibrillation scheduled for PFA or CBA procedures Biomarkers of interest: high-sensitive troponin, CRP, NT-proBNP Data collection: Blood samples will be collected at baseline, immediately after the procedure, 24 hours after, and three months after. Statistical analysis: Comparisons of biomarker levels between PFA and CBA groups. Results: Comparison of biomarker levels between PFA and CBA groups at each time point. Changes in biomarker levels over time within each group. Correlation analysis between biomarker levels and clinical outcomes, such as AF recurrence, LA stiffness, complications, and hospitalization.

Official Title
-----------------
Biomarkers in Pulsed Field Ablation Versus Cryoballoon Ablation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Symptomatic paroxysmal or persistent atrial fibrillation. Age between 18 and 75 years. Exclusion criteria: Prior atrial fibrillation ablation. History of significant bleeding or thromboembolic events within the last 6 months. History of severe renal or liver disease. History of malignancy within the last 5 years. History of autoimmune disease or immunodeficiency. Significant mitral stenosis or other significant valvular heart disease. Pregnancy or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To see if PFA vs CBA increase left atrium stifness by measuring NT-proBNP values after procedures |  | One year |
Study of CM310 in Subjects With Allergic Rhinitis

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of CM310 in patients with seasonal allergic rhinitis, and observing the quality of life, PK, PD characteristics, and immunogenicity of subjects.

Detailed Description
-----------------
Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis Under Background Treatment

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Biological: CM310
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 18-65. Understand the nature of research and sign the Informed Consent Form voluntarily. Take effective contraception measures throughout the study period. Exclusion Criteria: Used other investigational drugs. Plan to participate in other studies during this clinical trial. With malignant or benign tumors of the nasal cavity. Other reasons the researcher believes that the subject is not suitable to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CM310 group<br> | Biological: CM310<br>* IL-4Rα monoclonal antibody<br>|
| Placebo Comparator: Placebo<br> | Biological: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events (AEs) | Incidence (including number of patients, events and percentage) of adverse events. | Week 12 |
Spondylodiscitis Cases at Assiut University Hospital

Study Overview
=================
Brief Summary
-----------------
The term Spondylodiscitis (SD) involves infection of the vertebra (Spondylitis), infection of the intervertebral disc (Discitis), or both (Spondylodiscitis) Spondylodiscitis is a rare disease accounting for 2.7% of all cases of pyogenic osteomyelitis, with incidence varying from 1 per 100,000/year to 1 per 250,000/year However, there is evidence that the incidence is rising due to longer life expectancy for patients with increasing incidence of chronic debilitating disease including diabetes mellitus, malignancies ,(Human Immunodeficiency Virus (HIV)/ Acquired Immunodeficiency Syndrome (AIDs) , immunosuppressive therapy, increasing numbers of Intravenous drug users , and spinal surgeries. Pathogens can reach the spine either by: hematogenous spread, direct external inoculation, or spread from contiguous tissues harboring these pathogens. The hematogenous route is the predominant one, allowing seeding of infection from distant sites into the vertebral column. Since spondylodiscitis has not been studied in a clinical trial at our hospital, and information about this disease has come from retrospective case series and isolated cases. In this study, we present our prospectively collected patient clinical and epidemiological data in order to provide a proper management

Official Title
-----------------
Epidemiology, Clinical Features and Diagnosis of Spondylodiscitis at Assiut University Hospital

Conditions
-----------------
Spondylodiscitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who come into Assiut University Hospital and outpatient clinic with clinical symptoms suggestive of spondylodiscitis in all age groups including patients with known medical conditions and patients who underwent previous spine surgeries (post operative spondylodiscitis) Exclusion Criteria: No patients will be excluded
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measuring the inflammatory markers in patient with spondylodiscitis (Ex. C reactive protein (CRP) in mg/dl) | collect all patients with spondylodiscitis who come to Assiut University Hospital, measure the inflammatory markers and follow up them after medical or surgical treatment | collect data for 1 year and follow up for 1 year | 
| Describing of pain severity according to Pain severity scale and follow up after treatment | collect all patients with spondylodiscitis who come to Assiut University Hospital, measure the pain severity and follow up pain improvement after medical or surgical treatment | collect data for 1 year and follow up for 1 year |
Verticalization Criteria for Pelvic Ring Tumor Lesions Treated by Percutaneous Screw Fixation and Cementoplasty

Study Overview
=================
Brief Summary
-----------------
Evaluate early functional outcomes following percutaneous screw fixation or cementoplasty for pelvic ring tumor lesions.

Official Title
-----------------
Verticalization Criteria for Pelvic Ring Tumor Lesions Treated by Percutaneous Screw Fixation and Cementoplasty: A Retrospective Multicentric Study

Conditions
-----------------
Pelvic Ring Tumor Lesions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion : - Individuals with cancer who underwent percutaneous screw fixation or cementoplasty either for prophylactic consolidation or treatment of pathologic fractures in pelvic ring tumors. Exclusion criteria : minors incompetent adults refused to participate in the study pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Verticalization | Time (day) required following the procedure to obtain verticalization | During hospitalization, mainly less than 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event | adverse event during procedure or hospitalization | During hospitalization, and follow-up | 
| Duration of hospitalization | The duration of hospitalization will be measured between the day and time of arrival at the hospital and the day and time of discharge from the hospital | Mainly less than 3 days | 
| Long-term effectiveness in preventing pathological fractures of the pelvic ring | Absence of pelvic ring fracture during follow-up | 3 months after the procedure, and during follow-up, up to 5 years |
Advanced Platelet-rich Fibrin Combined With Open Debridement in Management of Suprabony Periodontal Defects

Study Overview
=================
Brief Summary
-----------------
in this clinical trial, patients with periodontal defects will be treated with advanced platelet-rich fibrin in conjunction with open debridement

Detailed Description
-----------------
two groups of patients with suprabony defects, one will be treated with advanced platelet-rich fibrin in conjunction with open debridement and the other will be treated with open debridement alone. subjects will be evaluated for evidence of bone formation after 6 months of therapy

Official Title
-----------------
Clinical and Radiographic Evaluation of Advanced Platelet Rich Fibrin and Open Debridement in Management of Periodontal Suprabony Defects

Conditions
-----------------
Periodontitis, Adult

Intervention / Treatment
-----------------
* Biological: advanced PRF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with periodontal suprabony defects. Exclusion Criteria: pregnant females. smokers. systemic disease that contraindicate surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group 1<br> | Biological: advanced PRF<br>* advanced PRF+ surgery<br>|
| Sham Comparator: group 2<br> | Biological: advanced PRF<br>* advanced PRF+ surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical evaluation | Rate of probing pocket depth reduction | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| radiographic evaluation | Rate of bone formation by digital radiography | 6 months |
A Survey on Psychosomatic Health Status of Chinese Population

Study Overview
=================
Brief Summary
-----------------
A Survey on Psychosomatic Health Status of Chinese Population

Detailed Description
-----------------
This is a nationwide cross-sectional study to investigate psychosomatic symptoms among genral population in China. This study will also focus on the relationship between psychosomatic symptoms and functions and wellbeing.

Official Title
-----------------
A Survey on Psychosomatic Health Status of Chinese Population

Conditions
-----------------
Psychosomatic; Disorder, Multiple, Well-Being, Psychological

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years old and above; Able to complete the scale independently; Subjects read informed consent through online questionnaires and agreed to cooperate with relevant assessments. Exclusion Criteria: Individuals with severe physical disease; Individuals with cognitive impairment; Individuals who cannot finish the online survay independently.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| General Pupulation of China<br>General Pupulation of China | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychosomatic health status | symptoms severity measured by the symptoms checklist of this study | Baseline |